Tim Hirst

Gamma Vaccines Pty Ltd. develops broad-spectrum vaccines against influenza and bacterial pneumonia. The firm is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company was founded by Tim Hirst, Mohammed Alsharif and Jean Petre in July 2009 and is headquartered in Manuka, Australia.

GPN Vaccines Ltd. is an Australian biotechnology company that is developing a vaccine called Gamma-PN™ to protect against all strains of Streptococcus pneumoniae, which causes life-threatening pneumonia, bacteremia, meningitis, and middle ear infections. The company is based in Adelaide, Australia, and Tim Hirst has been the CEO since 2017. This disease is responsible for causing 1-2 million deaths worldwide each year, particularly in children.

Gamma Vaccines Pty Ltd. develops broad-spectrum vaccines against influenza and bacterial pneumonia. The firm is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company was founded by Tim Hirst, Mohammed Alsharif and Jean Petre in July 2009 and is headquartered in Manuka, Australia.

Gamma Vaccines Pty Ltd. develops broad-spectrum vaccines against influenza and bacterial pneumonia. The firm is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company was founded by Tim Hirst, Mohammed Alsharif and Jean Petre in July 2009 and is headquartered in Manuka, Australia.